List view / Grid view

Otsuka Pharmaceutical Co. Ltd (Otsuka)

 

Results of clinical phase III study of once-monthly aripiprazole IM depot formulation for the treatment of schizophrenia presented at APA

7 May 2012 | By H. Lundbeck A/S

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from a clinical phase III clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Trial results were presented in four poster presentations at…

NDA for aripiprazole depot formulation for maintenance treatment of adult patients with schizophrenia accepted

22 November 2011 | By H. Lundbeck A/S (Lundbeck)

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the US Food and Drug Administration (FDA) has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit…

Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide

11 November 2011 | By H. Lundbeck A/S (Lundbeck)

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a development and commercialisation agreement for up to five products in the psychiatry field, including aripiprazole depot formulation and OPC-34712 from Otsuka and up to three highly innovative earlier stage projects from Lundbeck.